Pathway development consortium announces publication in human gene therapy on the application of fda's accelerated approval pathway for aav gene therapies for patients with duchenne muscular dystrophy

- publication in human gene therapy provides rationale for the use of microdystrophin expression levels as a surrogate endpoint reasonably likely to predict clinical benefit for aav gene therapy intended for treatment of patients with duchenne muscular dystrophy -
SLDB Ratings Summary
SLDB Quant Ranking